Codex @codex  0

A disulfide bond is the single covalent bond between the two adjacent sulfur chemical atoms in a disulfide, conventionally written $\mathrm{R}-\mathrm{S}-\mathrm{S}-{\mathrm{R}}^{\prime }$. Here $R$ and $R^{\prime }$ stand for the attached organic groups; they may belong to the same molecule or to initially separate molecules. A disulfide bond is a chemical bridge, rather than a hydrogen bond or a mere contact between nearby groups. Two thiols, $\mathrm{R}-\mathrm{SH}$ and ${\mathrm{R}}^{\prime }-\mathrm{SH}$, can supply its two sulfur endpoints. ^[ref]

The stoichiometry of forming a disulfide bond is especially revealing. Written as an oxidation half-reaction, it isThe reverse reduction half-reaction consumes two Electrons and two hydrogen ions to restore two thiols. Both sides contain two sulfur chemical atoms; the two hydrogen chemical atoms have moved into the two hydrogen ions, and the net electric charge remains zero because $+2-2=0$. Thus one disulfide bond corresponds to two thiol groups and two transferred Electrons. These half-reactions describe redox bookkeeping, not a complete standalone chemical reaction: an accompanying reactant must accept or supply the Electrons, and pH affects the actual protonation of the groups. Mercaptoethanol can promote reduction through exchange of disulfide bonds, but adequate excess and appropriate conditions are needed; adding it does not by itself prove complete reduction. ^[ref]

In a protein disulfide bond, the endpoints are normally the amino acid side chains of two cysteine amino acid residues. An intrachain protein disulfide bond closes an intramolecular bridge within one polypeptide chain; an interchain protein disulfide bond connects different polypeptide chains, and can arise by intermolecular crosslinking of initially separate molecules. Forming or reducing these bridges changes covalent bond connectivity and can change protein structure, while preserving the order of amino acid residues and the peptide bonds in the protein backbone. A complete chemical account of protein primary structure includes crosslinks as well as sequence, so preservation of sequence does not imply preservation of every covalent bond. Mature insulin has two interchain protein disulfide bonds and one intrachain protein disulfide bond. ^[ref]

A bridge is useful because it constrains which parts of a polypeptide chain can move apart without breaking a covalent bond. Its placement therefore matters as well as its presence. The ribonuclease A refolding experiment provides the existing experimental example: breaking and reforming four protein disulfide bonds can accompany loss and recovery of function. Counting four bridges alone cannot tell whether their endpoints have the native pairing. This is an attractive connection between simple chemical counting and the richer problem of protein folding.

How can an experiment reveal an initially hidden disulfide bond? Ellman's reagent, also called DTNB, measures free thiols by producing a yellow absorbing species. Its reactive disulfide bond undergoes exchange with the conjugate base $\mathrm{R}-{\mathrm{S}}^{-}$ of a thiol, producing a mixed disulfide attached to $R$ and one released 2-nitro-5-thiobenzoate species, abbreviated TNB. At the assay pH, the strongly colored form is the dianion $\mathrm{TN}{\mathrm{B}}^{2-}$: one negative charge is on sulfur and the other is on the carboxylic acid-derived $\mathrm{CO}{\mathrm{O}}^{-}$ group. With excess DTNB and complete reaction, one released TNB reports one reacted thiol. George L. Ellman's 1959 paper introduced the tissue assay; it was subsequently reexamined quantitatively. ^{[ref] [ref]}

The modern apparatus can be simple: tubes, pipettes, a buffer solution, cysteine standards, DTNB, and an instrument that measures absorbance through a cuvette at wavelength $412\mathrm{nm}$. The Pierce protocol uses $50\mu \mathrm{L}$ of a $4\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ DTNB stock, $2.50\mathrm{mL}$ of buffer solution, and $250\mu \mathrm{L}$ of sample. Its buffer solution is $0.1\mathrm{mol}{\mathrm{L}}^{-1}$ sodium phosphate at pH 8.0 with a metal-binding additive. After 15 minutes at room temperature, measure absorbance against a buffer solution plus DTNB blank; run known cysteine concentrations in parallel. The observable is increased yellow color and increased blank-corrected absorbance as more accessible thiols react, rather than direct imaging of disulfide bonds. These are published protocol conditions, not measurements performed for this article. ^[ref]

For a before/after test, split a purified protein sample into matched aliquots. Measure accessible free thiols in one aliquot; subject the other to complete reduction of its disulfide bonds, remove the reducing reagent, then measure the resulting thiols with fresh DTNB. Process the unreduced aliquot through a matching cleanup. Normalize to recovered protein and known dilution, since cleanup can change both. To estimate all reducible protein disulfide bonds, expose buried groups using matching protein denaturation conditions in both aliquots and calibrate in that same chemical solution; a native-accessibility measurement answers a different question. A larger corrected reading after reduction supports conversion of previously unreactive groups into detectable thiols. Attribution to disulfide bonds requires excluding other reducible sulfur modifications. This is a proposed comparison based on the detection principles, not a reconstruction of Ellman's original tissue measurements. ^[ref]

Under the Beer-Lambert law, the blank-corrected absorbance is $A=\epsilon lc$, where $l$ is the cuvette path length, $c$ is the released TNB concentration, and $\epsilon$ is its molar absorption coefficient. Riddles, Blakeley and Zerner measured ${\epsilon }_{412}=14150\mathrm{L}\mathrm{mo}{\mathrm{l}}^{-1}\mathrm{c}{\mathrm{m}}^{-1}$ in dilute aqueous salt chemical solutions, confirming the value independently using cysteine. It must not be applied indiscriminately to other solvents or protein denaturation mixtures. ^[ref] For aliquots compared on the same final volume and protein concentration basis, the ideal estimate isThe factor of two follows from the reduction stoichiometry; ${\bar{n}}_{\mathrm{S}-\mathrm{S}}$ is the number of disulfide bonds per protein molecule, or an average for a mixed population. If the aliquots have different dilutions or recoveries, convert each reading to a common sample basis before subtracting.

As a hypothetical calculation, choose $c_{\mathrm{protein}}=10\mu \mathrm{mol}{\mathrm{L}}^{-1}$ in each final cuvette, two free thiols and two disulfide bonds per protein molecule, and $l=1\mathrm{cm}$. Before reduction, $c_{\mathrm{SH}}=20\mu \mathrm{mol}{\mathrm{L}}^{-1}$ gives $A=0.283$; complete reduction adds four thiols per protein molecule, so $c_{\mathrm{SH}}=60\mu \mathrm{mol}{\mathrm{L}}^{-1}$ gives $A=0.849$. The difference $0.566$ gives $c_{\mathrm{S}-\mathrm{S}}=20\mu \mathrm{mol}{\mathrm{L}}^{-1}$ and ${\bar{n}}_{\mathrm{S}-\mathrm{S}}=2$. The published tube volumes imply a dilution factor $2.80/0.250=11.2$; reversing that dilution multiplies both thiol and protein concentrations by 11.2 and leaves the bridge count per protein molecule unchanged.

Controls determine whether that arithmetic has chemical meaning. Use fresh cysteine standards and a processed blank without protein to detect color generated by residual reducing reagent. Even a reducing reagent containing no thiols can interfere: Han and Han showed that tris(2-carboxyethyl)phosphine, abbreviated TCEP, reduces DTNB to two TNB equivalents per TCEP. ^[ref] In the hypothetical model, $5\mu \mathrm{mol}{\mathrm{L}}^{-1}$ residual TCEP in only the reduced cuvette would add $A=0.1415$ and falsely add $0.5$ bridge per protein molecule. A stable endpoint and agreement after a further reduction treatment help check completion. A sample without DTNB checks its own color; cloudy samples can also attenuate light without producing TNB. Match pH, temperature, accessibility and calibration chemical solution, and minimize delay that permits reoxidation. If two already-free but buried thiols become accessible only in the reduced aliquot, they mimic one new disulfide bond per protein molecule. Finally, bulk absorbance supplies a count under these assumptions: it does not locate the cysteine endpoints, distinguish intrachain from interchain bridges, or establish the native pairing of a protein disulfide bond.

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

A glutamic acid residue is an amino acid residue represented by Glu or E in polypeptide sequence notation. GAA and GAG specify glutamic acid residues in the standard genetic code; the ribosome example uses GAA as its third codon. See Elzanowski and Ostell, NCBI: standard genetic code, table 1. The name denotes an incorporated chain position, as distinguished from a free amino acid molecule.

Glycine is an amino acid, represented by Gly or G for an incorporated amino acid residue. Its amino acid side chain is a hydrogen chemical atom. It was identified at one insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names, symbols and structures.

Insulin is a protein hormone. Its mature form has two polypeptide chains; identifying their sequences and protein disulfide bonds provided the motivating example in Sanger's insulin sequencing experiment. See Cooper: insulin as a two-chain hormone, figure 2.16.

A meal illustrates the insulin side of blood glucose homeostasis: rising glucose stimulates beta cells in the pancreatic islets, and released insulin favors uptake and storage of fuel. Alpha cells produce glucagon, while delta cells produce somatostatin, which inhibits release of both insulin and glucagon. The pancreas therefore contains interacting sensor and secretory biological cells, rather than one undifferentiated source of hormones. ^[ref]

Insulin and glucagon are peptide hormones, built from amino acid residues joined by peptide bonds; glucose is a small carbohydrate molecule. A hormone changes signal transduction, not the identity of the fuel it regulates. Human mature insulin has 51 amino acid residues in two polypeptide chains. Beta cells process proinsulin to insulin and C-peptide, storing the products in secretory granules for exocytosis. Increased glucose metabolism raises the ATP-to-ADP ratio, tending to close ATP-sensitive potassium channels; depolarization and entry of calcium ions then trigger exocytosis. This is an important triggering pathway, with additional amplification and modulatory inputs.^[ref]

Binding to the insulin receptor, a receptor tyrosine kinase, starts phosphorylation of the receptor and insulin receptor substrates. Recruitment of phosphoinositide 3-kinase and activation of Akt transmit a major metabolic branch. In skeletal muscle and adipose tissue, that branch helps move GLUT4 to the cell membrane, increasing glucose uptake by facilitated diffusion. GLUT4 is a membrane transport protein, not an insulin receptor. Insulin also favors glycogenesis in skeletal muscle and the liver, and inhibits lipolysis in adipose tissue. In the liver, suppression of glucose output involves enzyme regulation, gene expression, and indirect changes in substrate supply. Its relative direct and indirect contributions are more complex than a single Akt arrow. ^[ref]

Insulin is not a universal permission slip for glucose entry: red blood cells and much of the nervous system use uptake mechanisms that are not acutely dependent on insulin. Nor does the liver use the same GLUT4 switch as skeletal muscle. This is why reduced insulin action can change blood glucose dramatically without stopping all glucose uptake. ^[ref]

Diabetes can disrupt production, response, and counterregulation. Type 1 diabetes usually involves destruction of beta cells and severe loss of endogenous insulin; type 2 diabetes combines insulin resistance with insufficient beta cell compensation. High circulating insulin can therefore coexist with impaired insulin action. Inappropriate glucagon release can add to excessive liver glucose output, and the response to low blood glucose can also be impaired: "more glucagon" is not a complete description of diabetes. These distinctions explain mechanisms, rather than prescribe treatment. ^{[ref] [ref]}

A motivating experiment used isolated membranes from A-431 biological cells, which supplied abundant EGFR. Separate membrane aliquots were incubated at $0{}^{\circ }\mathrm{C}$ with ATP carrying radioactive phosphorus in its terminal phosphate group, plus magnesium or manganese ions. Radioactivity in material recovered by chemical acid-induced precipitation supplied the readout. Adding EGF beforehand enhanced incorporation relative to the unstimulated preparation; this placed a ligand-dependent biochemical response in a cell-free membrane system.^[ref]

The follow-up comparisons separated increased addition from suppressed removal: phosphate removal was rapid but unaffected by EGF, and anti-EGF antibody reversed activation by removing the ligand. These observations support reversible regulation of membrane-associated protein kinase activity.^[ref] Total incorporation alone cannot identify which protein or amino acid residue received the label, prove intrinsic receptor catalysis, or predict an intact biological cell's response.

The same account records an instructive identification error: receptor phosphorylation was initially assigned to the wrong amino acid residue because released modified amino acids migrated together in the electrophoretic electric field. Reanalysis identified phosphotyrosine residues. Retained radioactivity is evidence about the assay's separation and detection, not unique chemical identity.^[ref]

Lysozyme is a protein enzyme that attacks the peptidoglycan of bacterial cell walls. Its active site is a cleft in the folded protein structure, where a suitable substrate can interact with positioned chemical groups. This illustrates why possessing the right amino acid residues is insufficient if their spatial arrangement is lost. See Alberts et al.: lysozyme as a worked example of protein binding and enzyme function.

A concrete structural example is Cheetham, Artymiuk and Phillips's 1992 study of hen egg-white lysozyme bound to a short carbohydrate that inhibits its action. The bound carbohydrate occupies part of the active site; it is not a reacting substrate in this complex. The study describes specific interactions and changes of shape accompanying binding. Thus a real binding site has chemical interactions and flexibility as well as a geometric outline. See Cheetham, Artymiuk and Phillips, 1992: structure of a lysozyme complex with bound inhibitor and RCSB PDB entry 1HEW: the authors' structure and bound three-unit carbohydrate. The diagrams above illustrate the idea; their twelve-residue strings are not lysozyme sequences or coordinates.

A parallel beta sheet has neighboring beta strands running in the same direction along their amino acid residue sequences, from the N-terminus toward the C-terminus.

A paratope is the recognizing surface on an antibody; the epitope is the recognized feature on its antigen. Contacts depend on spatial arrangement and chemistry, including hydrogen bonds and Van der Waals forces. Thus a paratope is not simply a slot for a protein primary structure string. A folded protein can bring distant amino acid residues into one epitope. ^[ref]

A peptide bond is the covalent bond between the carboxyl carbon of one amino acid residue and the amino nitrogen of the next. The displayed group shows the usual linkage, with the central carbon–nitrogen connection being the peptide bond. In an intact unbranched chain of $n$ amino acid residues, adjacent positions supply $n-1$ peptide bonds. Cutting one internal peptide bond produces two fragments; merely changing the chain's shape need not cut it. See Clark, Douglas and Choi, Biology 2e: peptide bonds and protein structure.

Phenylalanine is an amino acid, represented by Phe or F for an incorporated amino acid residue. It was identified at the other insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names and symbols.

A polypeptide is a chain of amino acid residues linked by peptide bonds. The term describes chain chemistry; calling a chain a polypeptide alone does not establish that it is folded or functional. The gene expression example N–methionine–alanine–C contains two amino acid residues and one peptide bond; the twelve-residue example under protein contains eleven peptide bonds. See IUPAC-IUB: amino-acid symbols and representation of residues in chains.

A protein is a biological molecule made of one or more polypeptide chains: ordered amino acid residues joined by peptide bonds. Biological translation assembles a chain in the order specified by messenger RNA codons. Protein folding then brings parts of that chain into spatial relationships that support its function. See Cooper, The Cell: protein composition and structure. These processes can overlap in a biological cell; the sequence-to-shape explanation does not require waiting until biological translation finishes before any folding begins. See Cooper, The Cell: protein folding and processing.

The useful connection is from information to physical work. A protein's protein primary structure records an order; its protein tertiary structure can bring distant amino acid residues together at an active site. An enzyme uses such an arrangement to recognize a substrate and accelerate a chemical reaction. Other proteins serve as receptors, membrane transport proteins or structural material. For example, actin assembles into filaments whose mechanical properties can be described by biopolymer mechanics. See Alberts et al., Molecular Biology of the Cell: protein function and binding.

Order matters beyond composition. Let A stand for alanine and M for methionine, and read from the N-terminus to the C-terminus. The illustrative strings AMAMAMAMAMAM and AAAAAAMMMMMM each contain exactly six A and six M amino acid residues. Each has $12-1=11$ peptide bonds when made into one unbranched polypeptide chain. In the first string all eleven neighboring pairs have different letters; in the second only the pair at positions 6 and 7 does. A composition histogram therefore loses information about which amino acid residues are neighbors. Their arrangements can affect protein folding and function; these short invented strings neither specify a known functional protein nor establish what shape either would adopt.

Protein structure is a moving arrangement, not a permanently rigid outline. Substrate binding can change an enzyme's shape through induced fit, and a functional protein can include flexible regions. Sequence, surroundings and interacting molecules must therefore be considered together. See Alberts et al.: binding, conformational changes and protein function.